Cargando...
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...
Gardado en:
Main Authors: | , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado: |
AboutScience Srl
2018-10-01
|
Series: | AboutOpen |
Assuntos: | |
Acceso en liña: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/135 |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|